Bamlanivimab infusion experience at one academic emergency department.
作者信息
Yoo Michael J, Long Brit J, Schauer Steven G
机构信息
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, United States of America.
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, United States of America.
出版信息
Am J Emerg Med. 2022 Jun;56:266-267. doi: 10.1016/j.ajem.2021.06.076. Epub 2021 Jul 12.
Abstract
摘要
相似文献
1
Bamlanivimab infusion experience at one academic emergency department.一家学术性急诊科的巴姆兰尼单抗输注经验。
Am J Emerg Med. 2022 Jun;56:266-267. doi: 10.1016/j.ajem.2021.06.076. Epub 2021 Jul 12.
2
Implementation of an Emergency Department-Embedded Infusion Center for the Administration of Monoclonal Antibody Therapy in Patients With Early COVID-19 Infection.实施急诊病房内输液中心，为早期 COVID-19 感染患者输注单克隆抗体治疗。
J Infus Nurs. 2022;45(1):41-48. doi: 10.1097/NAN.0000000000000453.
3
Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.针对 2019 年冠状病毒病（COVID-19）的巴姆洛单抗的真实世界经验：一项病例对照研究。
Clin Infect Dis. 2022 Jan 7;74(1):24-31. doi: 10.1093/cid/ciab305.
4
Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.早期使用单克隆抗体LY-CoV555（巴瑞替尼单抗）对老年疗养院患者死亡率和住院率的临床影响：一项多中心回顾性研究。
Cureus. 2021 May 10;13(5):e14933. doi: 10.7759/cureus.14933.
5
Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities.在急性后期和长期护理机构中成功提供巴利昔单抗的卫生系统。
J Am Med Dir Assoc. 2022 Jan;23(1):141-145. doi: 10.1016/j.jamda.2021.11.029. Epub 2021 Dec 8.
6
Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.巴瑞替尼和依特赛韦单抗用于新型冠状病毒肺炎暴露后预防
Med Lett Drugs Ther. 2021 Oct 18;63(1635):163-164.
7
New-onset seizures after bamlanivimab infusion.巴姆兰尼单抗输注后新发癫痫发作。
Br J Clin Pharmacol. 2022 Mar;88(3):1395-1397. doi: 10.1111/bcp.15066. Epub 2021 Sep 16.
8
Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.巴瑞替尼可改善新冠病毒疾病患者的住院率和死亡率：一项系统评价与荟萃分析。
J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.09.003. Epub 2021 Sep 14.
9
Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents.严重急性呼吸综合征冠状病毒2中和单克隆抗体对长期护理机构居民住院率和死亡率的影响。
Aging Dis. 2022 Oct 1;13(5):1523-1531. doi: 10.14336/AD.2022.0205.
10
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?我们需要巴伦尼单抗吗？埃特司韦单抗是否是治疗新冠肺炎的关键？
Expert Opin Biol Ther. 2021 Nov;21(11):1359-1362. doi: 10.1080/14712598.2021.1985458. Epub 2021 Sep 29.
引用本文的文献
1
Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.巴尼韦单抗可降低急诊返诊率和住院率，并可能降低资源匮乏边境医院的 COVID-19 负担。
West J Emerg Med. 2022 Mar 17;23(3):302-311. doi: 10.5811/westjem.2021.10.52668.
Zotero 插件